Reason for request

Re-assessment of the improvement in actual benefit

Moderate clinical added value in first-line treatment of unresectable malignant pleural mesothelioma

  • ALIMTA has marketing authorisation, in combination with ciscplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
  • It is the standard treatment for this disease. 

 


Clinical Benefit

Substantial

-


Clinical Added Value

moderate

-


Therapeutic use

-

Contact Us

Évaluation des médicaments